多发性骨髓瘤与白细胞介素-6  

Multiple myeloma and interleukin-6

作　　者：王建军[1] 洪丽萍[1] 汤立军[1] 

机构地区：[1]中南大学生物科学与技术学院分子生物学研究中心,长沙410078

出　　处：《生命科学》2010年第11期1192-1195,共4页Chinese Bulletin of Life Sciences

基　　金：国家自然科学基金项目(30400529);湖南省杰出青年基金(04JJ1006);中南大学米塔尔学生创新基金资助项目(08MX26)

摘　　要：白细胞介素-6是多发性骨髓瘤(multiple myeloma,MM)瘤细胞生长和生存的关键因子,也是MM患者发病的主要因子。IL-6/IL-6R系统通过不同通路影响多发性骨髓瘤瘤细胞生长并导致患者骨损害、类风湿性关节炎等一系列并发症。针对IL-6/IL-6R系统的治疗方法将给MM的治疗带来重大的进展。Interleukin-6 is a key growth and survival factor,which is involved in tumorigenesis of multiple myeloma.The proliferation of malignant cells in multiple myeloma are affected through different pathways of IL-6/IL-6R,which also could lead to bone damage,rheumatoid arthritis and some other complications in patients.Treatment of MM targeted IL-6/IL-6R system will provide a new therapeutic approach based on interruption of IL-6 mediated tumor cell growth in future.

关 键 词：IL-6/IL-6R GP130 多发性骨髓瘤 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R733.3[医药卫生—内科学]